INTRODUCTION
Isolates and clinical specimens from cases of meningococcal disease referred to the Meningococcal Reference Unit (MRU) of the Health Protection Agency (HPA) form an essential component in the surveillance of meningococcal disease in England and Wales. Although meningococcal disease is a relatively rare infection, the presentation and high case fatality continue to keep the disease prominent in the public perception. Surveillance of confirmed meningococcal disease, including surveillance of the diversity of causative strains, is essential to aid cluster management and to inform vaccine development. Over the past decade there have been important changes in the methods for diagnosis and characterization of the organism, and also in the epidemiology of the disease itself. We review the changes in laboratory surveillance methods and the trends in epidemiology detected by the HPA MRU over an 11-epidemiological-year period from 1993/94 to 2003/04. sterile body sites, primarily cerebrospinal fluid (CSF) or blood. Neisseria meningitidis isolates are received at the MRU from laboratories in England and Wales for species confirmation and phenotypic characterization using biochemical and serological techniques Wedege et al., 1990; Kuipers et al., 2001 ; http: //neisseria.org/nm/typing/mabs/panel.shtml). In the early 1990s, the number of clinically diagnosed cases of meningococcal disease reported by statutory notifications began to exceed the number of laboratoryconfirmed cases. The problem of reduced case ascertainment by culture confirmation (Ramsay et al., 1997) , probably due to changes in clinical practice, such as a decrease in the number of lumbar punctures being performed (Richards & Towu-Aghantse, 1986 ) and the administration of antibiotics to patients before their admission to hospital (Bohr et al., 1983; Cartwright et al., 1992) , was addressed by the development of PCR-based assays for the detection of meningococcal DNA (Guiver & Borrow, 2001) . PCR testing was introduced as a confirmation test, to augment laboratory surveillance of meningococcal disease, in October 1996 (Davison et al., 1996; Kaczmarski et al., 1998) . Detailed methods are given below.
(a) N. meningitidis isolate confirmation and characterization methods. N. meningitidis isolates were received at the MRU from laboratories in England and Wales for species confirmation and phenotypic characterization using biochemical and serological techniques. Following subculture, the organisms were biochemically confirmed by means of cysteine tripticase agar oxidative carbohydrate utilization tests (glucose, maltose, lactose and sucrose). The capsular polysaccharide serogroup was determined by means of co-agglutination using in-house-produced rabbit polyclonal antibodies absorbed onto killed Staphylococcus aureus suspensions Wedege et al., 1990; Kuipers et al., 2001) . The serogrouping reagent panel comprised serogroups A, B, C, X, Y, Z, 29E and W135. The in-house co-agglutination results were occasionally supplemented with commercial latex antigen kits (Meningite-5, bioMérieux, Wellcogen ACYW135 or B/Escherichia coli KI, BioStat). From July 1999, isolates were also screened for serogroups A, B and C by using murine mAbs supplied by the National Institute for Biological Standards and Control (NIBSC), South Mimms, UK, in a dot-blot ELISA format Wedege et al., 1990; Kuipers et al., 2001 ; http://neisseria.org/ nm/typing/mabs/panel.shtml). The serotype and sero-subtype of isolates were also determined in the dot-blot ELISA Wedege et al., 1990 ) using a NIBSC meningococcal mAb panel that included serotypes P3.1, P2.2a, P2.2b, P3.4, P3.11, P3.14, P3.15, P3.21and P2.22, and sero-subtypes P1.1, P1.2, P1.3, P1.4, P1.5, P1.6, P1.7, P1.9, P1.10, P1.12, P1.13, P1.14, P1.15, P1.16 and P1.19 , where the class 1 outer-membrane protein (OMP) PorA (sero-subtype) is designated P1.* and the class 2 or class 3 OMP PorB (serotype) is designated P2.* or P3.*, respectively. All the mAbs were available for the period 1993 to 2003 except P1.13 (used from September 1993), P1.19 (used from July 2002) and P2.16 (discontinued from November 1994). Serotype P3.4 was most often characterized by reactions with a serotype 4 variant mAb initially sourced from W. Zollinger, Walter Reed Army Institute of Research, Silver Spring, MD, from December 1995, although some isolates were also reactive with another less sensitive variant serotype 4 mAb supplied by NIBSC from 1993 until July 2001, and initially obtained from the Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Bilthoven, The Netherlands (Urwin et al., 1998) .
(b) Non-culture case confirmation of meningococcal disease by PCR methods. In 1995/96, the MRU introduced DNA-based non-culture detection of meningococci by means of a PCR ELISA. The rapid expansion of the PCR ELISA service offered to England and Wales from October 1996 increased the number of samples to be handled and necessitated a transfer in 1998 to an automated system, the Perkin-Elmer Applied Biosystems (ABI) 7700 realtime PCR system using Taqman chemistry (Guiver et al., 2002) . PCR assays using primers and probes were designed to detect IS1106 (an insertion sequence) (Davison et al., 1996; Ni et al., 1992) , ctrA (part of the meningococcal capsular biosynthesis locus) (Borrow et al., 1998; Guiver & Borrow, 2001) and siaD (encoding a sialyltransferase responsible for the addition of sialic acid residues to the polysialic acid chain of the capsule polysaccharide) (Guiver & Borrow 2001; Borrow et al., 1997) . Initially, because of the increased sensitivity achieved as a consequence of the multiple copies carried within the genome, the insertion sequence IS1106 was used in the PCR ELISA to screen samples for the presence of meningococcal DNA (Davison et al., 1996; Ni et al., 1992) , but its use was discontinued after 1996 when IS1106 was detected in other genera (Guiver & Borrow, 2001) . From 1997, all samples received at the MRU were screened for the presence of meningococcal DNA using ctrA, which detects meningococcal DNA from clinically significant serogroups (A, B, C, Y, W135, X and 29E) (Guiver & Borrow 2001) . siaD assays were used to confirm the serogroup of the sialic-acid-containing capsules for serogroups B and C (from 1997 to present) (Guiver & Borrow 2001; Borrow et al., 1997) and serogroups Y and W135 (from 1999) (Guiver & Borrow 2001; Borrow et al., 1998) . Serogroup A was confirmed by the mynA PCR assay from 2000 (Overlid et al., 1999 , Diggle et al., 2003 .
Improvements in DNA extraction procedures since 1995 have increased the efficacy of the non-culture confirmation methods and allowed the application of automated procedures. From 1997 to 2002, DNA extraction from EDTA whole blood samples was by capture column systems such as those supplied by Qiagen and Gentra (Flowgen) (Guiver & Borrow, 2001) , and for CSF, plasma or serum, the preferred method was DNAzol (Molecular Research Centre) (Guiver & Borrow, 2001) . Since 2002, the MRU has used the MagNApure (Roche Diagnostics) automated DNA extraction system to improve the quality and reproducibility of DNA extracts. Samples accepted for PCR testing include CSF, joint fluids, serum, plasma and EDTA whole blood.
Data. Information on laboratory-confirmed cases of meningococcal disease was stored on a database, and included information on the demographics of the cases (age, sex and region) and the characteristics of the infecting organism (for cultured isolates this included serogroup, serotype and sero-subtype, but for those cases that were identified by non-culture methods from clinical specimens, usually only the serogroup was recorded). Only cases confirmed by culture were assigned a phenotype (serogroup, serotype and sero-subtype), and among these, many were serotype or sero-subtype non-typeable (NT), because specific typing reagents were unavailable. Data on laboratory-confirmed cases of meningococcal disease referred to the MRU over the 11 epidemiological years 1993/94 to 2003/04 (July 1 1993 to June 30 2004) are presented. Analysing the data by epidemiological year takes into account the seasonal nature of meningococcal disease by centring the peak incidence, which occurs in the winter months. Deaths registered with the UK Office for National Statistics (ONS) attributed to meningococcal disease are routinely linked to laboratoryconfirmed cases, and this information is also presented here. Completeness of ascertainment was improved by the routine follow up of confirmed cases of meningococcal disease reported to the HPA Centre for Infections by laboratories in England and Wales, requesting referral to the MRU. Since 2000, the National Public Health Service for Wales has also been offering a diagnostic PCR, although positive specimens should be referred to the MRU.
RESULTS AND DISCUSSION

Disease incidence
In the early 1990s, the incidence of meningococcal disease was fairly stable, with around 1200 cases reported each year up to 1994/95, corresponding to an incidence of around 2?3 per 100 000 (Table 1) . In 1995/96, the reported incidence of disease increased by 39 % to 3?3 per 100 000, by a further 37 % to 4?6 per 100 000 in 1996/97, and still further by 19 % to peak at 5?4 per 100 000 in 1998/99 (test for trend in disease incidence by year, P <0?001). The incidence of laboratory-confirmed meningococcal disease caused by all serogroups declined to less than 3?0 per 100 000 in 2002/ 03 and 2003/04 (Table 1 ). The age distribution for all serogroups during this period was typical of meningococcal disease, with a high incidence in infants and young children and a small secondary peak in older teenagers. An age shift was discerned between 1994/95 and 1995/96, which persisted through the 1990s, with proportionately more cases occurring in older age groups, particularly in the 15-19 year age group (Fig. 1) .
Method of confirmation
The excess of notifications over laboratory-confirmed cases decreased after 1995/96 (Fig. 2) , following the introduction of direct PCR-based testing of clinical samples (Kaczmarski et al., 1998) (Table 2) . It was therefore possible to explain the increase in disease incidence at this time (Table 1) by improved case ascertainment rather than by a real change in disease incidence. However, Ramsay et al. (1997) found that while there were indeed improvements in ascertainment through laboratory reporting, shifts in the age and serogroup distribution, together with an increasing number of notifications ( Fig. 1 ), provided evidence of real, changing trends in disease. The introduction and provision of a free nationwide (UK) service for the non-culture (PCRbased) confirmation of meningococcal disease undoubtedly improved the quality of epidemiological information available. In 2002/03 and 2003/04, 47 and 45 %, respectively, of meningococcal cases were confirmed by PCR alone (Table 2) .
Increase in serogroup C disease
The increased incidence of laboratory-confirmed meningococcal disease after 1994/95 was mostly attributable to an increase in serogroup C cases. In particular, between 1994/ 95 and 1995/96, the number of cases of serogroup C disease more than doubled (Table 3) , and the proportion of cases directly attributable to serogroup C infection increased from 25 to 36 % (P <0?0001). After adjusting for the ungrouped cases (those cases confirmed as N. meningitidis by ctrA PCR testing but for which no serogroup was identified) that were likely to be due to serogroup C, the proportion of serogroup C cases increased to 40 % in 1995/96. Most of this sustained increase in serogroup C cases over the period 1993/94 to 1998/99 was due to the phenotypic combination of serotype 2a (Table 4) , serosubtype P1.5,2 (Table 5 ). The C : 2a : P1.5 phenotype increased as a proportion of serogroup C case isolates from 16 % in 1993/94 to a peak of 48 % in 2001/02 (Table 5 ). This hyperinvasive clone had previously been identified as a cause of hyperendemic disease in Canada (Whalen et al., 1995) and is associated with multilocus sequence type 11 (ST-11) (previously identified by multilocus enzyme electrophoresis as ET-37 complex). C : 2a strains are also associated with a higher fatality rate in the UK (Trotter et al., 2002a) .
Serogroup C conjugate vaccination
Introduction of meningococcal serogroup C conjugate (MCC) vaccines. As a result of this sustained increase in serogroup C disease, the UK accelerated its programme of clinical trials, and in 1999 the new MCC vaccines were licensed on the basis of safety and immunogencity data . In November of the same year, the MCC vaccines were incorporated into the routine infant Miller et al., 2001 ). This catch-up campaign ran until September 2000 and was phased by age group, those at highest risk being targeted first. The vaccine was well accepted, with coverage above 80 % in all but the oldest age groups (Trotter et al., 2002b) . Laboratory-confirmed cases of serogroup C in MCC-vaccinated individuals were investigated whenever possible (C. Auckland and others, unpublished results).
Impact of MCC vaccination. The phased introduction of MCC vaccines required accurate case confirmation to determine the effectiveness of vaccine intervention. The MRU was able to confirm the characterization of serogroup C case isolates, and, via the provision of the nonculture meningococcal PCR diagnosis and grouping service, give an accurate estimate of the levels of serogroup C infection in England and Wales.
The number of cases of serogroup C disease declined each year after the introduction of the vaccine from a high of 954 cases in 1998/99 (and 892 cases in 1999/00) to only 64 cases (Table 3) (Table 3) . Fig. 3 compares the number of cases in those aged under 20 years (those initially targeted in the vaccine campaign) and those aged 20 years or above. Short-term vaccine effectiveness was high in all age groups Ramsay et al., 2001; Trotter et al., 2004) . After 4 years, effectiveness remains high in children vaccinated when above the age of 5 months, but declines to low levels in children vaccinated routinely at 2, 3 and 4 months (Trotter et al., 2004) .
Significant herd immunity effects have resulted (Ramsay et al., 2003) in a lower prevalence of carriage in vaccinated compared to unvaccinated individuals (Maiden et al., 2002) , and benefits to older, unvaccinated age groups are now being observed. The distribution of serotypes, for those cases of serogroup C disease that were confirmed using culture methods, are described in Table 4 , and the major phenotypes (serogroup, serotype and sero-subtype) are described as the percentage of serogroup C isolates in Table 5 . The phenotypic profiles of disease-causing isolates have not changed substantially 2 7  1 3  1 2  2  3  2  W135  12  21  20  42  40  44  96  129  101  46  47  X  3  6  2  2  7  7  3  7  6  2  2  Y  2 6  2 1  2 5  2 1  3 2  2 3  2 8  2 8  2 9  1 7  2 8  Z/29E  3  1  2  1  3  1  4  7  0  0  1  UngroupedD  156  425  309  320  134  163  110  76  50  Total  1186  1228  1708  2337  2298  2778  2799  2446  1961  1477  1493 * NG, non-groupable isolates (due to non-expression of capsule with throat swab isolates from clinically confirmed cases or carrier isolates obtained from possible cases). DUngrouped isolates were tested by PCR, and although the presence of meningococcal DNA was confirmed (often in low amounts), it was not possible to determine the serogroup by siaD or mynA PCR assays.
following vaccination. In particular, there is no evidence of an increased frequency of B : 2a cases (Table 6 ) or other phenotypes (serotypes or serosubtype combinations) that were predominantly associated with serogroup C prior to the implementation of vaccination. There is no evidence that the vaccination programme has led to extensive capsular switching.
Serogroup B disease
Throughout the 11-year time period, serogroup B was the most common cause of meningococcal disease. The proportion of laboratory-confirmed serogroup B cases was 69 % in 1993/94, dropping to 46 % in 1996/97 as the number of serogroup C cases increased, but rising to 87 % in 2003/4 following the introduction of the MCC vaccine.
Although not as dramatic as that seen for serogroup C, the number of reported cases of serogroup B disease rose each year from 1995/96 to 2000/01 (Table 3) . Again, some of this increase may be explained by improved case ascertainment through PCR testing, although further insights can be gained by looking at the trends in the predominant phenotypes (Tables 6 and 7) .
Further subdivision of meningococcal serogroups by means of serological reagents to determine the serotype 312  305  615  596  557  668  552  261  147  74  45 *Total number of isolate-confirmed serogroup C cases; cases identified by PCR only were not characterized by serotype and serosubtype.
and sero-subtype (based on expressed OMPs) has allowed the discrimination of related cases of serogroup B for outbreak or cluster investigation. In addition, the immunogenic potential of the OMPs has stimulated the development of vaccines that include specific sero-subtypes, continued monitoring of which is necessary to inform the design of potential novel vaccines. The period 1993/94 to 2003/04 was the first in which consistent phenotypic surveillance using a fixed panel of mAbs was applied to all case isolates from England and Wales.
Serogroup B isolates showed greater phenotypic diversity with regard to serotype than serogroup C isolates (Table 6 ). In terms of serotype, there was a major shift in the proportion of cases attributable to B : 4 isolates; the number of cases increased more than tenfold between 1994/95 and 1995/96 (P <0?0001). However, this increase was in part due to the availability of an additional antiserotype 4 monoclonal antibody from December 1995 onwards, which was better at discriminating UK strains to serotype 4 than the one originally used. The corollary was a corresponding decrease in the number of B : NT isolates. Phenotypic combinations of serogroup : serotype : serosubtype have been used as surrogate markers for specific strains (Wedege et al., 1995; Caugant et al., 1987) . A number of phenotypic trends (strain population changes) were observed from 1993/94 to 2003/04: B : 15 : P1.7,16, which was important in the UK (and Europe) in the 1980s declined during the 11-year period, in the absence of any intervention. The increasing predominance of B : 4 : P1.4 (or B : 4/ NT : P1.4) case isolates over the 11 years, which has slowed latterly, suggests a gradual accumulation of immunity to this meningococcal phenotype. The continued usefulness of serotyping is shown by the increase in cases attributable to B : NT : P1.9 (from 2?8 % in 1993/94 to 11 % in 2003/04) and B : 1 : P1.14 (from 0?5 % to 15 %) meningococci. This is important, as it demonstrates a characteristic feature of meningococcal epidemiology, the natural turnover or variation in meningococcal antigens, whereby a particular strain emerges (e.g. B : 15 : P1.7,16), and then declines to be replaced by a new strain (e.g. B : 4 : P1.4), possibly in response to herd/host population immune responses. This has implications for vaccines designed around surface proteins such as PorA (sero-subtype) or PorB (serotype) and the timeliness with which they may need to be introduced and used.
Other serogroups
There was a 25 % increase in cases (from 96 to 129) caused by serogroup W135 in all ages between 1999/00 and 2000/01, which was largely due to an outbreak of W135 meningococcal disease among pilgrims returning from Saudi Arabia and their contacts (Hahne et al., 2002a, b The number of cases of serogroup Y disease remained stable at around 30 cases per year, and there were only minor fluctuations in the small numbers of cases due to other serogroups (A, 29E, X and Z), which rarely cause disease in the UK. The use of quadrivalent conjugate vaccines rather than the monovalent MCC vaccine may be more suited to countries in which the burden of disease from serogroup W135 and/or serogroup Y is higher.
Mortality
Deaths among laboratory-confirmed cases of meningococcal disease are shown in Table 8 . The overall case fatality ratio (CFR) remains around 6 %, despite evidence that death rates can be reduced in specialist centres (Booy et al., 2001 ; Thorburn et al., 2001) . Earlier work has shown meningococcal phenotype, in particular the C : 2a strain, and increasing age of the host to be associated with death (Trotter et al., 2002a) . 
Future directions
The characterization by serotyping of meningococcal isolates has identified predominant phenotypes and revealed epidemiological trends over the 11-year period. As molecular methods become more widely available and less costly it is possible that DNA-based typing may replace the conventional serological methods in the near future. The development and application of DNA-based typing for meningococci by PorA sequencing and multilocus sequence typing (MLST) is envisaged for routine surveillance within the next 5 years, and will improve the discrimination of isolates and increase their typeability. Surveillance by MLST will also allow the genetic relatedness of disease-causing meningococci to be studied, irrespective of their surface properties. Historical data for meningococcal disease surveillance currently rely on serological typing, and so links between molecular and serological schemes should be well established to enable consistent epidemiological analysis and surveillance.
Conclusions
Ongoing, high-quality laboratory surveillance is essential for monitoring the epidemiology of meningococcal disease; its output will inform the need for and assess the impact of vaccination programmes, and play a critical role in outbreak management.
